论文部分内容阅读
目的:对我院治疗的骨髓增生异常综合征(MDS)患者的临床资料进行分析,探讨阿米福汀治疗骨髓增生异常综合征的临床效果。方法:将我院48例骨髓增生异常综合征的患者,用阿米福汀进行临床治疗,每次在患者化疗之前0.5h,静脉滴注给药:600mg/m2,每次大约15min。结果:使用了阿米福汀治疗的患者,外周血和骨髓造血祖细胞都明显增殖,可以延迟细胞凋亡,具有细胞保护作用和减轻放化疗的毒副作用。结论:阿米福汀在治疗骨髓增生异常综合征时,有一定的作用,可以降低化疗的毒副作用,并且可以延迟细胞的凋亡。但目前我国使用阿米福汀治疗骨髓增生异常综合征的案例并不大,所以还有待于进一步的观察和临床研究。
Objective: To analyze the clinical data of patients with myelodysplastic syndrome (MDS) treated in our hospital and discuss the clinical effect of amifostine in the treatment of myelodysplastic syndrome. Methods: 48 cases of myelodysplastic syndrome in our hospital, with amifostine for clinical treatment, each time before chemotherapy 0.5h, intravenous infusion administration: 600mg / m2, each about 15min. Results: In patients treated with amifostine, peripheral blood and bone marrow hematopoietic progenitor cells were significantly proliferated, which could delay cell apoptosis, have cytoprotective effects and reduce the side effects of radiotherapy and chemotherapy. Conclusions: Amifostine plays a role in the treatment of myelodysplastic syndrome, which can reduce the side effects of chemotherapy and delay the apoptosis of cells. However, the current use of amifostine in the treatment of myelodysplastic syndrome cases is not large, so it needs further observation and clinical research.